Company research
Aptevo Therapeutics Inc.
CIK 1671584Updated Nov 6, 2026
SecurityAPVO · NASDAQ · equity
Historical securities (1)
APVTW · OTC · warrant · closed Mar 5, 2024APVO price & chart
Loading TradingView…
NASDAQ:APVO on TradingView ↗About the company
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trial, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
424B5 filing
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders
Items 1.01, 3.03, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
S-8 filing
Other Events
Items 8.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
424B4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 26,996,000Source | 15,146,000Source | 14,519,000Source | 15,624,000Source | 14,921,000Source | 19,902,000Source | 8,342,000Source | 17,629,000Source | 27,194,000Source | 15,591,000Source | 24,842,000Source | 34,215,000Source |
| Property, Plant and Equipment, NetUSD | 384,000Source | 614,000Source | 236,000Source | 432,000Source | 697,000Source | 268,000Source | 482,000Source | 789,000Source | 303,000Source | 543,000Source | 895,000Source | 1,462,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,061,000Source | 7,753,000Source | 9,797,000Source | 9,410,000Source | 8,066,000Source | 14,525,000Source | 2,139,000Source | 10,250,000Source | 21,619,000Source | 8,714,000Source | 16,904,000Source | 22,635,000Source |
| Assets, CurrentUSD | 22,649,000Source | 10,012,000Source | 10,798,000Source | 11,081,000Source | 9,579,000Source | 15,984,000Source | 3,607,000Source | 12,074,000Source | 23,081,000Source | 10,659,000Source | 19,066,000Source | 27,450,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 1,001,000Source | — | — | 1,459,000Source | — | — | 1,462,000Source | — | — | — |
| Operating Lease, Right-of-Use AssetUSD | 3,963,000Source | 4,520,000Source | 3,484,000Source | 4,111,000Source | 4,645,000Source | 3,650,000Source | 4,253,000Source | 4,766,000Source | 3,810,000Source | 4,389,000Source | 4,881,000Source | 5,303,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 9,604,000Source | 10,726,000Source | 8,478,000Source | 9,100,000Source | 10,458,000Source | 8,290,000Source | 9,815,000Source | 11,526,000Source | 9,813,000Source | 10,836,000Source | 12,621,000Source | 16,241,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 110,000Source | 82,000Source | 114,000Source | 99,000Source | 69,000Source | 114,000Source | 84,000Source | 66,000Source | 114,000Source | 84,000Source | 61,000Source | 48,000Source |
| Retained Earnings (Accumulated Deficit)USD | -269,217,000Source | -241,265,000Source | -288,264,000Source | -260,189,000Source | -236,164,000Source | -281,909,000Source | -253,985,000Source | -230,281,000Source | -275,115,000Source | -247,577,000Source | -223,447,000Source | -206,036,000Source |
| Stockholders' Equity Attributable to ParentUSD | 17,392,000Source | 4,420,000Source | 6,041,000Source | 6,524,000Source | 4,463,000Source | 11,612,000Source | -1,473,000Source | 6,103,000Source | 17,381,000Source | 4,755,000Source | 12,221,000Source | 17,974,000Source |
| Additional Paid in Capital, Common StockUSD | 286,499,000Source | 245,603,000Source | 294,191,000Source | 266,614,000Source | 240,558,000Source | 293,407,000Source | 252,428,000Source | 236,318,000Source | 292,382,000Source | 252,248,000Source | 235,607,000Source | 223,962,000Source |
| Liabilities and EquityUSD | 26,996,000Source | 15,146,000Source | 14,519,000Source | 15,624,000Source | 14,921,000Source | 19,902,000Source | 8,342,000Source | 17,629,000Source | 27,194,000Source | 15,591,000Source | 24,842,000Source | 34,215,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,614,000Source | 5,882,000Source | 5,188,000Source | 4,891,000Source | 5,419,000Source | 4,760,000Source | 5,393,000Source | 6,298,000Source | 6,050,000Source | 6,207,000Source | 7,224,000Source | 8,706,000Source |
| Operating Lease, Liability, CurrentUSD | 800,000Source | 700,000Source | 919,000Source | 800,000Source | 700,000Source | 892,000Source | 800,000Source | 700,000Source | 866,000Source | 800,000Source | 700,000Source | 400,000Source |
| Accounts Payable, CurrentUSD | — | — | 1,162,000Source | — | — | 890,000Source | — | — | 877,000Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 3,990,000Source | 4,800,000Source | 3,290,000Source | 4,200,000Source | 5,000,000Source | 3,530,000Source | 4,400,000Source | 5,200,000Source | 3,763,000Source | 4,629,000Source | 5,397,000Source | 6,079,000Source |
| Other Liabilities, NoncurrentUSD | — | 14,000Source | — | — | 14,000Source | — | — | 14,000Source | — | 0Source | — | — |
| Additional Financial Items | ||||||||||||
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,456,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 2,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,456,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -17,411,000Source | 8,027,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 35,000Source | 61,000Source | 240,000Source | 352,000Source | 567,000Source | 901,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 57,000Source | 180,000Source | 96,000Source | 1,069,000Source | 2,193,000Source | 1,802,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,965,000Source | -6,575,000Source | -25,592,000Source | -23,785,000Source | -11,730,000Source | -21,022,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | -29,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 29,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 871,000Source | 0Source | 38,497,000Source | 15,595,000Source | 5,998,000Source | -2,616,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,467,000Source | 12,267,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -7,094,000Source | -6,575,000Source | 12,905,000Source | -8,190,000Source | -5,732,000Source | -23,667,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | — | 22,635,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 100,000Source | 200,000Source | 96,000Source | 1,069,000Source | 2,193,000Source | 1,802,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 200,000Source | 400,000Source | 600,000Source | 900,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | 9,650,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | -47,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 37,182,000Source |
| General and Administrative ExpenseUSD | — | — | 3,566,000Source | 2,110,000Source | 2,747,000Source | 2,898,000Source | 2,913,000Source | 2,847,000Source | 11,772,000Source | 10,224,000Source | 11,771,000Source | 13,873,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,239,000Source | 1,013,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,549,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -17,411,000Source | 8,027,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,028,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,794,000Source | -6,408,000Source | -27,538,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 61,000Source | 112,000Source | 87,000Source | 22,000Source | 140,000Source | 72,000Source | 345,000Source | 472,000Source | 578,000Source | -4,027,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 5,800,000Source | — | — | 872,000Source | 0Source | 37,940,000Source | 10,036,000Source | — | 6,934,000Source |
| Increase (Decrease) in Accounts Payable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 3,114,000Source |
| Operating Income (Loss)USD | — | — | -7,610,000Source | -5,213,000Source | -6,443,000Source | -6,226,000Source | -6,837,000Source | -6,480,000Source | -26,312,000Source | -24,602,000Source | -28,878,000Source | -28,641,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 61,000Source | 112,000Source | 87,000Source | 22,000Source | 140,000Source | 72,000Source | 345,000Source | 472,000Source | 578,000Source | -4,027,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,549,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -17,411,000Source | 8,027,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -5.31Source | -151.29Source | -6.41Source | -1,581.81Source | -87.27Source | -87.38Source | -1.42Source | 1.57Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -5.31Source | -151.29Source | -6.41Source | -1,581.81Source | -87.27Source | -87.38Source | -1.42Source | 1.57Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 1,196,364Source | 41,008Source | 1,060,678Source | 4,051Source | 315,535Source | 276,137Source | 12,234,661Source | 5,100,310Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 1,196,364Source | 41,008Source | 1,060,678Source | 4,051Source | 315,535Source | 276,137Source | 12,234,661Source | 5,102,914Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,566,000Source | 2,110,000Source | 2,747,000Source | 2,898,000Source | 2,913,000Source | 2,847,000Source | 11,772,000Source | 10,224,000Source | 11,771,000Source | 13,873,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,697,000Source | -6,408,000Source | -25,967,000Source | -24,130,000Source | -18,650,000Source | 7,014,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.48Source | — | — | — | — | — | -87.38Source | -1.52Source | 1.37Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.48Source | — | — | — | — | — | -87.38Source | -1.52Source | 1.37Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,239,000Source | 1,013,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,028,000Source | -5,101,000Source | -6,356,000Source | -6,204,000Source | -6,794,000Source | -6,408,000Source | -27,538,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 4,044,000Source | 3,103,000Source | 3,696,000Source | 3,328,000Source | 3,924,000Source | 3,633,000Source | 14,540,000Source | 14,378,000Source | 17,107,000Source | 17,882,000Source |
Offerings
Registration 333-298483
- Offering price
- market-price
- Ticker
- APVO
Registration 333-293010
- Offering amount
- $25,000
- Offering price
- market-price
- Ticker
- APVO
Registration 333-290663
- Offering amount
- $25,000
- Offering price
- market-price
- Ticker
- APVO
Registration 333-288959
- Offering amount
- $25,000
- Offering price
- market-price
- Ticker
- APVO
Registration 333-288061
- Gross proceeds
- 8011250.0
- Net proceeds
- 7450463.0
- Deal price
- 3.25
- Shares
- 2465000
- Offering price
- $3.25
- Ticker
- APVO
Registration 333-287244
Registration 333-284969
- Gross proceeds
- 50000000.0
- Offering amount
- $50,000,000
- Offering price
- at-the-market
- Ticker
- APVO
Registration 333-285476
Filing attachments
apvo-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML Refined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further strengthening mipletamig's readiness for Phase 2 development Substantial reduction in infusion reaction frequency and severity improves the patient treatment experience without compromising planned therapeutic dosing Achie…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-10-26
Exhibit 99.1 Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplant Transplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence supporting mipletamig's potential to improve outcomes in frontline AML Aptevo expects the RAINIER dose optimization trial to concl…
Read attachment ↗apvo-ex4_1.htm · 8-K · 2026-10-23
Exhibit 4.1 APTEVO THERAPEUTICS INC. AMENDMENT NO. 6 TO RIGHTS AGREEMENT This Amendment No. 6 (this “Amendment”), dated as of October 23, 2026, to the Rights Agreement, dated November 8, 2020 (as amended and/or restated from time to time, the “Rights Agreement”), is entered into by and between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, as rights agent (the “Rights Agent”). Capitalized terms used but not defined herein sha…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-10-14
Exhibit 99.1 Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA - October 14, 2026 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its multispecific…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-09-24
Exhibit 99.1 Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development Company making critical progress in scalable manufacturing and preparing the lead trispecific candidate for future human testing Trispecifics combine three complementary cancer-fighting functions in one molecule, enabling a coordinated approach to recognizing cancer, activating immune cells and addressing tumor defenses SEATTLE, WA - September 24, 2026 - Aptevo Therapeutics Inc. (“Aptevo” or the “C…
Read attachment ↗apvo-ex99_1.htm · 8-K · 2026-09-03
EX-99.1 2 apvo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA - September 3, 2026 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical be…
Read attachment ↗